The results of our study showed that the risk of major amputation in patients with diabetes after ACT with no-option CLTI is increased by inherited thrombophilia—MTHFR A1298C gene mutations, smoking, and higher CRP levels before ACT treatment. This evidence concerns the gene MTHFR and diabetes mellitus.